Stopping some MS drugs in pregnancy may raise relapse risk
Key Takeaway
Stopping some MS treatments during pregnancy can raise the risk of relapse and disability.
What They Found
MS does not worsen most pregnancy outcomes. Less is known about how newer MS treatments affect babies exposed during pregnancy. Stopping some treatments during pregnancy can raise the risk of relapse and disability. Drug labels usually put a baby's safety ahead of the mother's safety. More information is emerging about babies exposed to MS treatments during pregnancy and breastfeeding.
Who Should Care and Why
This review is about people with MS who are planning to have children. It also covers people with MS who are pregnant or breastfeeding. Treatment decisions can be especially difficult when MS has been very active. They can also be difficult when stopping a treatment risks a return of disease activity. The review discusses how these decisions involve both the parent's health and the baby's safety.
Important Considerations
You should know this is a review, not a study testing a treatment. It does not give a sample size. The effects of newer MS treatments on exposed babies remain uncertain.
AI-generated summary — for informational purposes only, not medical advice
Categories:
You May Also Like
11/1/2026
Researchers compared blood from people with childhood-onset MS and healthy volunteers. They found DN
Read More
11/1/2026
In 24 people with severe MS, stem cell treatment lowered signs of inflammation and nerve damage for
Read More
11/1/2026
A review of 49 studies finds special brain scans can detect MS-related inflammation, but scan method
Read More
10/6/2026
Researchers found immune cells that swap surface tags in MS. An MS treatment removed them in the stu
Read More
10/6/2026
In children with MS, immune attacks on the brain and spinal cord may go unchecked. See what research
Read More
10/1/2026
A study links a body chemical to MS inflammation and shows that blocking its source eases symptoms i
Read MoreUnderstanding MS Research
Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like The Lancet. Neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.